Targeting TMEM205 mediated drug resistance in ovarian clear cell carcinoma using oncolytic virus
Abstract Background Ovarian clear cell carcinoma (OCCC) accounts for approximately 8-10% of epithelial ovarian cancers in the United States. Although it is rare, OCCC usually presents with treatment challenges and the overall prognosis is far worse than high grade serous ovarian cancer HGSOC. The ob...
Saved in:
Main Authors: | Uksha Saini (Author), Brentley Q. Smith (Author), Kalpana Deepa Priya Dorayappan (Author), Ji Young Yoo (Author), G. Larry Maxwell (Author), Balveen Kaur (Author), Ikuo Konishi (Author), David O'Malley (Author), David E. Cohn (Author), Karuppaiyah Selvendiran (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2022-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Correction: Targeting TMEM205 mediated drug resistance in ovarian clear cell carcinoma using oncolytic virus
by: Uksha Saini, et al.
Published: (2023) -
Upregulation of TMEM45A Promoted the Progression of Clear Cell Renal Cell Carcinoma in vitro
by: Jiang H, et al.
Published: (2021) -
Giving Oncolytic Viruses a Free Ride: Carrier Cells for Oncolytic Virotherapy
by: Alberto Reale, et al.
Published: (2021) -
Oncolytic Virus Immunotherapy
Published: (2022) -
Progress of oncolytic virotherapy for neuroblastoma
by: Xiao-Tong Chen, et al.
Published: (2022)